The BioNTech SE ADR BNTX inched 0.49% higher to $118.22 Friday, on what proved to be an all-around mixed trading session for ...
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
Investor's Business Daily on MSN11d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A RecoveryBioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
12d
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
The BioNTech SE ADR BNTX rallied 1.59% to $117.64 Thursday, on what proved to be an all-around favorable trading session for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback